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Abstract
Background: Parkinson’s disease (PD) is a devastating neurodegenerative disorder characterized by progressive
motor debilitation, which affects several million people worldwide. Recent evidence suggests that glial cell
activation and its inflammatory response may contribute to the progressive degeneration of dopaminergic neurons
in PD. Currently, there are no neuroprotective agents available that can effectively slow the disease progression.
Herein, we evaluated the anti-inflammatory and antioxidant efficacy of diapocynin, an oxidative metabolite of the
naturally occurring agent apocynin, in a pre-clinical 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse
model of PD.
Methods: Both pre-treatment and post-treatment of diapocynin were tested in the MPTP mouse model of PD.
Diapocynin was administered via oral gavage to MPTP-treated mice. Following the treatment, behavioral,
neurochemical and immunohistological studies were performed. Neuroinflammatory markers, such as ionized
calcium binding adaptor molecule 1 (Iba-1), glial fibrillary acidic protein (GFAP), gp91phox and inducible nitric oxide
synthase (iNOS), were measured in the nigrostriatal system. Nigral tyrosine hydroxylase (TH)-positive neurons as well
as oxidative markers 3-nitrotyrosine (3-NT), 4-hydroxynonenal (4-HNE) and striatal dopamine levels were quantified
for assessment of the neuroprotective efficacy of diapocynin.
Results: Oral administration of diapocynin significantly attenuated MPTP-induced microglial and astroglial cell
activation in the substantia nigra (SN). MPTP-induced expression of gp91phox and iNOS activation in the glial cells
of SN was also completely blocked by diapocynin. Notably, diapocynin markedly inhibited MPTP-induced oxidative
markers including 3-NT and 4-HNE levels in the SN. Treatment with diapocynin also significantly improved
locomotor activity, restored dopamine and its metabolites, and protected dopaminergic neurons and their nerve
terminals in this pre-clinical model of PD. Importantly, diapocynin administered 3 days after initiation of the
disease restored the neurochemical deficits. Diapocynin also halted the disease progression in a chronic mouse
model of PD.
Conclusions: Collectively, these results demonstrate that diapocynin exhibits profound neuroprotective effects in a
pre-clinical animal model of PD by attenuating oxidative damage and neuroinflammatory responses. These findings
may have important translational implications for treating PD patients.
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Background
Parkinson’s disease (PD) is the most common neurode-
generative movement disorder, estimated to affect 1% of
the population over 65 years of age. It is a chronic and
progressive disease characterized predominantly by rest-
ing tremors, bradykinesia, muscular rigidity and postural
instability, along with several non-motor symptoms [1].
The pathological hallmarks of PD are the depletion of
striatal dopamine caused by degeneration of dopamin-
ergic neurons in the substantia nigra (SN) region of the
midbrain, appearance of cytoplasmic inclusions, known
as Lewy bodies in surviving neurons of the SN, and acti-
vation of glial cells [2,3].
Although the etiologic mechanisms of PD are poorly
understood, recent reports implicate brain inflamma-
tion and oxidative stress play an important role in dis-
ease pathogenesis [2,4]. Microglia and astrocytes are
major mediators of neuroinflammation in PD. Several
reports have demonstrated the activation of microglial
cells and astroglial cells in close proximity to the
damaged or dying dopaminergic neurons in SN [5].
Levels of nitrite (NO2
−), a metabolite of nitric oxide
(•NO and inducible nitric oxide synthase (iNOS) are
higher in the central nervous system of human PD
cases and in animal models of PD [6]. Consistent with
this finding, iNOS knockout animals were resistant to
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-
induced dopaminergic neuronal loss in the SN [7].
One of the major sources of reactive oxygen species
(ROS) in neurodegeneration is NADPH oxidase, a mul-
timeric enzyme that generates both superoxide O2
−
(O2 and H2O2 [8]. The reaction between O2
− and
•NO forms peroxynitrite (ONOO-), another key player
of dopaminergic neurodegeneration in PD. Moreover,
4-hydroxynonenal (4-HNE), an unsaturated aldehyde
derived from lipid hydroperoxidase, is reported to
mediate the induction of neuronal apoptosis in the
presence of oxidative stress [9]. Collectively, these
findings strongly suggest that mitigation of neuroin-
flammation and oxidative stress may be a viable neu-
roprotective strategy for treatment of PD.
Several inhibitors of NADPH oxidase have been tested
for their anti-inflammatory and antioxidant effects
in dopaminergic cells [10]. For example, apocynin
(4-hydroxy-3-methoxyacetophenone), a plant-derived
antioxidant, has been widely used as an NADPH oxidase
inhibitor in in vitro and in vivo experimental models of
PD [10-12]. However, apocynin failed to protect dopa-
minergic neurons against rotenone-mediated neurotox-
icity in the absence of glial cells [4]. In vivo, apocynin has
been shown to form diapocynin, a dimer of apocynin,
resulting in the inhibition of NADPH oxidase [13].
Thus, in the present study, we synthesized the di-
meric derivative diapocynin and tested its antioxidant
and anti-inflammatory efficacies in mouse models of
PD. The results presented here show that diapocynin
suppresses MPTP-induced glial activation, attenuates
nigral expression of proinflammatory molecules,
reduces oxidative stress and protects the nigrostriatal
axis after MPTP administration. Collectively, these
results suggest that additional pre-clinical development
of diapocynin may yield an effective neuroprotective
and anti-neuroinflammatory drug capable of arresting
the progression of PD.
Methods
Animals and treatment
Eight-week-old male C57BL/6 mice weighing 24 to
28 g were housed in standard conditions: constant
temperature (22 ± 1°C), humidity (relative, 30%) and a
12 h light/dark cycle. Use of the animals and protocol
procedures were approved and supervised by the Insti-
tutional Animal Care and Use Committee (IACUC) at
Iowa State University (Ames, IA, USA) To assess the
neuroprotective effect of diapocynin, we first used low
doses of diapocynin (100 and 150 mg/kg/day) via oral
gavage, but these doses showed only a moderate effect
in attenuating MPTP-induced neurochemical deficits.
Therefore, we used a 300 mg/kg dose of diapocynin in
the subacute MPTP model of PD for detailed
characterization of the neuroprotective efficacy of dia-
pocynin. This 300 mg/kg dose was chosen based on
apocynin, which has been used at a similar dose range
in amyotrophic lateral sclerosis (ALS) and Alzheimer's
disease mouse models [14].
In the subacute MPTP regimen, mice received 25 mg/
kg/day MPTP-HCl in saline intraperitoneally for 5 con-
secutive days. Diapocynin was dissolved in 10% ethanol
1 day before the MPTP insult and the drug treatment
continued for 11 days. Animals were subjected to mea-
surements of inflammatory markers, neurotransmitter
levels, behavioral changes and neuronal damage at vari-
ous time points. Control mice received equivolumes of
the vehicle solution.
In the post-treatment regimen, diapocynin was
administered 3 days after the MPTP treatment. For
chronic MPTP treatment, mice received 2 doses
of MPTP (25 mg/kg/dose, s.c.) and 2 doses of pro-
benecid (250 mg/kg/dose, i.p.) per week for 5 con-
secutive weeks. Mice received 3 doses of diapocynin
(100 mg/kg/day) per week by oral gavage, and the
drug treatment started 1 week before MPTP injec-
tions, continued throughout the MPTP injection
period and extended for another 45 days of post-
MPTP treatment. After all treatments, animals were
subjected to behavioral, neurochemical and histological
measurements.
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High-performance liquid chromatography (HPLC) analysis
of striatal dopamine and its metabolite levels
Samples were prepared and quantified, as described pre-
viously [15,16]. On the day of analysis, neurotransmitters
from striatal tissues were extracted using an antioxidant
extraction solution (0.1 M perchloric acid, containing
0.05% Na2EDTA and 0.1% Na2S2O5) and isoproterenol
(as internal standard). Dopamine, 3,4-dihydroxyphenyl-
acetic acid (DOPAC) and homovanillic acid (HVA) were
separated isocratically by a reversed-phase column with
a flow rate of 0.6 ml/min. An HPLC system (ESA, Inc,
Bedford, MA, USA) with an automatic sampler equipped
with refrigerated temperature control (Model 542; ESA,
Inc) was used for these experiments.
HPLC/mass spectrometry (MS) analysis of diapocynin
Diapocynin from the striatum and SN was quantified
using the Agilent 1100 Series LC/MS binary pump (Agi-
lent, Santa Clara, CA, USA), PDA detector (UV diode
array detector) and an autosampler. On the day of ana-
lysis, a 20 μl sample was passed through the 0.2 μm filter
at the eluent flow rate of 0.25 ml/min. Negative-ion, at-
mospheric pressure chemical ionization was used at
amplitude 1.5 volts, and manual MS/MS was done. The
mobile phase used in LC/MS consisted of a gradient elu-
tion. Solvent A was 480:20:0.38 water:methanol:ammo-
nium acetate (v/v/w) and solvent B was 20:480:0.38
water:methanol:ammonium acetate (v/v/w). The stan-
dards series were taken as 0.3 μg, 1.0 μg, 3.0 μg, 10 μg,
and 30 μg. The actual molecular weight of diapocynin is
329.1 g/mol, but by breaking the molecule in MS/MS it
becomes 313.9 g/mol by elimination of one methyl mol-
ecule. The retention time for the diapocynin peak was
1.9 minutes. Data were fit to a straight line by linear re-
gression analysis using Quant analysis software (Agilent,
Santa Clara, CA, USA).
Western blotting
Mice were sacrificed 4 or 7 days after MPTP treatment,
and striatum and SN tissues were dissected. Brain lysates
containing equal amounts of protein were loaded in each
lane and separated in a 10 to 15% SDS-polyacrylamide
electrophoresis gel, as described previously [15,17]. The
membranes were then incubated with primary anti-
bodies (anti-TH (Chemicon, Temecula, CA, USA), anti-
Iba-1 (Abcam, Cambridge, UK), anti-GFAP (Chemicon),
anti-iNOS (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), anti-gp91phox (Abcam), anti-3NT (Chemicon)
and anti-4-HNE (R&D Systems, Minneapolis, MN,
USA)). Next, membranes were incubated with Alexa
Fluor 680 goat anti-mouse or Alexa Fluor 680 donkey
anti-goat (Invitrogen, Carlsbad, CA, USA) or IRDye 800
donkey anti-rabbit (Rockland, Gilbertsville, PA, USA)
secondary antibodies. To confirm equal protein loading,
blots were reprobed with a β-actin antibody (Sigma-
Aldrich, St Louis, MO, USA) at 1:10000 dilution. West-
ern blot images were captured with a LI-COR Odyssey
machine (LI-COR, Lincoln, NE, USA). The Western blot
bands were quantified using ImageJ software (National
Institutes of Health (NIH), Bethesda, MD, USA).
Immunohistochemistry
One day after the last MPTP treatment, mice were per-
fused with 4% paraformaldehyde (PFA) and post-fixed
with PFA and 30% sucrose, respectively. Next, fixed
brains were cut into 30 μm sections and were incubated
with primary antibodies (anti-Iba-1 (Abcam), anti-GFAP
(Chemicon), anti-iNOS (Santa Cruz Biotechnology),
anti-3NT (Chemicon), anti-gp91phox (Abcam), anti-TH
(Chemicon) and anti-4HNE (R&D)) overnight at 4°C.
Appropriate secondary antibodies (Alexa Fluor 488 or
594 or 555; Invitrogen) were used, followed by incuba-
tion with 10 μg/ml Hoechst 33342 (Invitrogen) for 5
minutes at room temperature to stain the nucleus. Sec-
tions were viewed under a Nikon inverted fluorescence
microscope (Model TE-2000U; Nikon, Tokyo, Japan);
images were captured with a SPOT digital camera (Diag-
nostic Instruments, Inc, Sterling Heights, MI, USA).
3,3'-Diaminobenzidine (DAB) immunostaining and
stereological counting
DAB immunostaining was performed in striatum and
SN sections, as described previously [3,18]. Briefly,
30 μm sections were incubated with either anti-TH
antibody (Calbiochem, Billerica, MA, USA; rabbit anti-
mouse, 1:1800 dilution) or anti-Iba-1 (Abcam; goat anti-
mouse, 1:1000 dilution) or anti-GFAP (Chemicon;
mouse anti-mouse, 1:1000 dilution) antibody, followed
by incubation with biotinylated anti-rabbit or goat or
mouse secondary antibody. Total numbers of tyrosine
hydroxylase (TH)-positive neurons in SN were counted
stereologically with Stereo Investigator software (MBF
Bioscience, Williston, VT, USA), using an optical
fractionator [16,19].
Fluoro-Jade B (FJB) and TH double labeling
On the day of staining, sections were incubated with
anti-TH antibody (Chemicon), followed by Alexa Fluor
568 donkey anti-mouse (Invitrogen) secondary antibody.
Then FJB staining was done on the same sections by the
modified FJB stain protocol, including incubation in
0.06% potassium permanganate for 2 minutes and
0.0002% FJB stain for 5 minutes. Sections were viewed
under a Nikon inverted fluorescence microscope (Model
TE-2000U; Nikon) and images were captured with a
SPOT digital camera (Diagnostic Instruments, Inc).
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Figure 1 (See legend on next page.)
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Behavioral measurements
An automated device (Model RXYZCM-16; Accuscan,
Columbus, OH, USA) was used to measure the spontan-
eous activity of mice. The activity chamber was 40 × 40
× 30.5 cm, made of clear Plexiglas and covered with a
Plexiglas lid with holes for ventilation. Data were col-
lected and analyzed by a VersaMax Analyzer (Model
CDA-8; AccuScan). Before any treatment, mice were
placed inside the infrared monitor for 10 minutes daily
for 3 consecutive days to train them. Five days after the
last MPTP injection, open field and rotarod experiments
were conducted. Locomotor activities were recorded for
10 minute test sessions. A speed of 20 rpm was used in
the rotarod experiment. Mice were given a 7 to 10 mi-
nute rest interval to prevent stress and fatigue.
Data analysis
Data analysis was performed using Prism 4.0 software
(GraphPad Software, Inc, San Diego, CA, USA). Raw
data were first analyzed using one-way analysis of vari-
ance and then Tukey’s post-test was performed to com-
pare all treatment groups. Differences with P <0.05 were
considered significant.
Results
Diapocynin enters brain and attenuates MPTP-induced
striatal neurotransmitter depletion
Male C57BL/6 mice were treated with diapocynin by
oral gavage daily and then inflammatory, neurochemical,
behavioral and histological studies were performed at
various time intervals, as depicted in Figure 1A. To as-
sess the neuroprotective effect of diapocynin, we first
used two lower doses of diapocynin (100 and 150 mg/
kg/day) and measured the dopamine level from striatum
(Figure 1B). Both 100 and 150 mg/kg/day doses of dia-
pocynin afforded some protection against MPTP-
induced striatal dopamine loss, but it was not significant
(Figure 1B). Therefore, we increased the dosage of
diapocynin to 300 mg/kg/day and then evaluated the
neuroprotective effects. Before determining the neuro-
protective properties of diapocynin, the ability of diapo-
cynin to cross the blood-brain barrier was examined.
The LC/MS results showed a significant accumulation of
diapocynin in the SN and striatum of the brain following
the oral gavage treatment of diapocynin (300 mg/kg/day)
(Figure 1C,D).
Following 300 mg/kg/day diapocynin treatment, mice
were sacrificed and brains were processed for HPLC
neurochemical analysis (Figure 1E,G). We quantified
levels of dopamine and its metabolites, DOPAC and
HVA, in striatum following diapocynin treatment. As
shown in Figure 1E, MPTP injection led to a >75% re-
duction in striatal dopamine levels compared with the
striata of control mice. Remarkably, diapocynin treat-
ment significantly protected against MPTP-induced stri-
atal dopamine depletion (Figure 1E). Diapocynin
treatment also significantly restored DOPAC and HVA
levels in MPTP-treated mice (Figure 1F,G).
In order to determine whether diapocynin interferes
with the toxic metabolic conversion of MPTP to MPP+
by MAO-B, we measured the level of MPP+ in striatum
3 h after the final MPTP injection. We found that diapo-
cynin had no effect on striatal levels of MPP+ (MPTP
mice, 1860 ± 569 ng/g; MPTP plus diapocynin mice,
1775 ± 586 ng/g). Next, we also tested whether diapocy-
nin treatment alone alters neurochemical levels in the
striatum. As shown in Figure 1E,G, oral administration
of diapocynin (300 mg/kg/day) alone for 12 days did
not alter striatal dopamine levels. Also, diapocynin treat-
ment did not produce behavioral abnormalities (data
not shown).
Diapocynin inhibits MPTP-induced glial activation
in the SN
Next, we determined if diapocynin protected against
MPTP-induced microglial activation and astrogliosis.
As shown in Figure 2, a significant increase in the ex-
pression of ionized calcium binding adaptor molecule 1
(Iba-1) and glial fibrillary acidic protein (GFAP) in SN of
the MPTP-treated group was observed. DAB immunos-
taining of Iba-1 in MPTP nigral brain tissue showed an
increased number of amoeboid-shaped microglial cells
with thick processes, indicative of active microgliosis
(Figure 2A). DAB immunostaining of GFAP in MPTP-
treated mice showed excessive astrogliosis, as measured
by increased size and processes thickness in GFAP-
positive cells (Figure 2D).
(See figure on previous page.)
Figure 1 Diapocynin enters brain and attenuates MPTP-induced depletion of neurotransmitters. (A) Treatment schedule of MPTP-injected
mice with diapocynin. (B) Mice were treated with two doses of diapocynin (100 and 150 mg/kg/day) and seven days after the last dose of MPTP
treatment, striatal dopamine level was measured using high-performance liquid chromatography (HPLC). Quantification of diapocynin in the
substantia nigra (SN) and striatum of mice. Mice were administered diapocynin (300 mg/kg/day) by oral gavage 24 h before MPTP treatment, and
co-treatment with MPTP (25 mg/kg/day) was continued for 5 days, and post-treatment with MPTP (25 mg/kg/day) lasted 6 days. Seven days after
the last injection of MPTP, SN and striatum were dissected out and quantified for diapocynin. (C) Standard curve of diapocynin standards ranging
from 0.3 μg to 30 μg. (D) Quantification of diapocynin in SN and striatum. Seven days after the last MPTP treatment, striatal (E) dopamine,
(F) 3,4-dihydroxyphenyl-acetic acid (DOPAC) and (G) homovanillic acid (HVA) were measured by HPLC. Data are means ± SEM of eight to ten
mice per group. ***P <0.001 versus the control group; *P <0.05 vs the MPTP group; #P <0.01 vs the MPTP group; aP <0.01 vs the control group.
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Importantly, diapocynin strongly inhibited MPTP-
induced microgliosis, as demonstrated by the very few
Iba-1-positive microglial cells in the drug-treated group
(Figure 2A). Also, diapocynin significantly decreased
MPTP-induced increases in GFAP-positive astroglial
cells in the mouse SN (Figure 2D). Western blot analysis
for Iba-1 and GFAP also revealed that diapocynin sup-
presses nigral Iba-1 (Figure 2B and C) and GFAP
(Figure 2E,F) protein expression in MPTP-treated mice.
Together, these data suggest that diapocynin significantly
attenuates glial cell activation in the nigral regions of the
MPTP mouse model of PD.
Diapocynin inhibits MPTP-induced iNOS expression in
mouse SN
iNOS, a key proinflammatory enzyme, is typically elevated
in disease conditions [3]. We observed a marked increase
in the expression of iNOS in the SN of MPTP-treated mice
as compared to control mice (Figure 3A,B). However, dia-
pocynin attenuated MPTP-induced expression of iNOS
protein (Figure 3A,B). Additionally, immunofluorescence
analysis for iNOS in the SN sections shows that MPTP
treatment led to a marked increase in nigral iNOS protein
expression, and that iNOS co-localized with GFAP-positive
astrocytes and Iba-1-positive microglial cells (Figure 3C,D).
Figure 2 Diapocynin inhibits activation of microglia and astrocytes in the substantia nigra (SN) of MPTP-treated mice. (A)
3,3'-Diaminobenzidine (DAB) immunostaining of Iba-1 in SN. (B) Representative Western blots illustrating the expression of Iba-1 in SN. (C) Bar
graph showing quantitative densitometric analysis of Iba-1/β-actin ratio ± SEM in SN of 6 mice per group. (D) DAB immunostaining of glial
fibrillary acidic protein (GFAP) in SN region of ventral midbrain. (E) Representative Western blots illustrating the expression of GFAP in SN. (F) Bar
graph showing mean Western blot GFAP/β-actin ratios ± SEM in SN of 6 mice per group. Images were captured at 30× magnification. **P <0.01
vs the control group; *P <0.05 vs the MPTP group.
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Consistent with its inhibitory effect on glial cell activation,
diapocynin suppressed MPTP-induced expression of iNOS
(Figure 3C,D). These results demonstrate that diapocynin
effectively suppresses the expression of the proinflamma-
tory molecule iNOS in vivo in the SN of MPTP-treated
mice.
Diapocynin attenuates MPTP-induced activation of
microglial NADPH oxidase
NADPH oxidase is a major source of ROS in the brain.
Recent findings suggest that NADPH oxidase-induced
oxidative stress plays a central role in nigral dopamin-
ergic neurodegeneration in PD patients and animal
models [20]. Western blot analysis showed an increased
expression of gp91phox, a key subunit of NADPH oxi-
dase, after MPTP injection compared to weak expression
in saline-treated mice (Figure 4A,B). Robust gp91phox
immunoreactivity was seen specifically in larger cells
with thick, shorter ramifications in the SN of MPTP-
treated mice (Figure 4C). Double immunolabeling stud-
ies confirmed that gp91phox immunoreactivity appeared
to co-localize with Iba-1-positive microglia (Figure 4C,
Figure 3 Diapocynin attenuates inducible nitric oxide synthase (iNOS) expression in the substantia nigra (SN) of MPTP-treated mice.
(A) Representative Western blots illustrating the expression of iNOS in SN. (B) Bar graph showing means of Western blot iNOS/β-actin
ratios ± SEM in SN of 6 mice per group. (C) Double labeling of glial fibrillary acidic protein (GFAP) and iNOS, and (D) Iba-1 and iNOS in the SN
region of ventral midbrain. Images were captured at 30× and 60× magnification. ***P <0.001 vs the control group; *P <0.05 vs the MPTP group.
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middle panel). Diapocynin treatment attenuated MPTP-
induced gp91phox protein expression in the Iba-1-
positive microglial cells in the SN (Figure 4C). In the
MPTP model of PD, gp91phox does not co-localize
with either astrocytes or dopaminergic neurons [20].
These results suggest that diapocynin effectively blocks
NADPH oxidase expression in response to MPTP.
Diapocynin inhibits formation of nitrotyrosine and
hydroxynonenal in the nigral dopaminergic neurons of
MPTP-treated mice
3-Nitrotyrosine (3-NT) has been widely used as a mar-
ker of nitric oxide-dependent oxidative stress [21]. West-
ern blot analysis demonstrated increased expression of
3-NT modified proteins in the SN of MPTP-treated
mice, while diapocynin treatment significantly sup-
pressed MPTP-induced 3-NT levels (Figure 5A,B). Fur-
ther confirmation came from immunolabeling of 3-NT
in the SN sections. In sections from MPTP-treated mice,
a dramatic increase in the expression of 3-NT, specific-
ally in the SN region of the ventral midbrain, was
observed. Notably, 3-NT co-localized (yellow color)
with TH-positive dopaminergic neurons (Figure 5C).
However, 3-NT expression was observed in very few
TH-positive dopaminergic neurons in the MPTP and
diapocynin co-treated animals (Figure 5C). These results
strongly suggest that diapocynin inhibits nitration of
TH-positive dopaminergic neurons in the nigra during
neurotoxic insult.
In addition to protein nitration, MPTP treatment sig-
nificantly increased oxidative damage in the nigral
regions, as measured by 4-HNE Western blot analysis
(molecular weight of 68kDa) (Figure 5D,E). However,
diapocynin strongly inhibited MPTP-induced expression
of this unsaturated aldehyde in the SN (Figure 5D,E).
Consistent with these findings, immunofluorescence
analysis of the MPTP-treated SN sections showed a dra-
matic increase in 4-HNE formation in the dopaminergic
neurons, as evidenced by TH and 4-HNE double immu-
nolabeling (Figure 5F). Interestingly, diapocynin treat-
ment abolished MPTP-induced 4-HNE generation in
dopaminergic neurons (Figure 5F). These results suggest
Figure 4 Diapocynin attenuates NADPH oxidase mediated inflammatory responses in the substantia nigra (SN) of MPTP-treated mice.
(A) Representative Western blots illustrating the expression of gp91phox (membrane-bound subunit of NADPH oxidase) in SN. (B) Bar graph
showing mean Western blot gp91phox/β-actin ratios ± SEM in SN of 6 mice per group. (C) SN tissue sections were double labeled for gp91phox
and Iba-1. Images were captured at 20× and 60× (insets) magnification. The SN zone is outlined in white dots. Inset pictures demonstrated
colocalization of Iba-1 and gp91phox. ***P <0.001 vs the control group; *P <0.05 vs the MPTP group.
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that diapocynin mitigates oxidative damage in nigral
dopaminergic neurons following MPTP neurotoxicity.
Diapocynin protects against MPTP-induced
neurodegeneration
Next, we determined whether diapocynin protects the
dopaminergic neurons against MPTP toxicity. MPTP
treatment led to degeneration of TH-positive dopamin-
ergic neurons and terminals in the SN and striatum
(Figure 6A, 2× magnification). Higher magnified 10×
pictures (Additional file 1: Figure S1A) clearly demon-
strated loss of neurons in substantia nigra pars compacta
(SNpc), substantia nigra lateralis (SNl) and substantia
nigra reticularis (SNr) regions of the nigral tract.
Figure 5 Diapocynin inhibits the formation of 3-nitrotyrosine (3-NT) and 4-hydroxynonenal (4-HNE) in the substantia nigra (SN) of
MPTP-treated mice. (A) Representative Western blots illustrating the expression of 3-NT in SN. (B) Bar graph showing mean Western blot
3-NT/β-actin ratios ± SEM in SN of 6 mice per group. (C) Double labeling of tyrosine hydroxylase (TH) and 3-NT in SN region of ventral midbrain.
(D) Representative Western blots illustrating the expression of 4-HNE in SN. (E) Bar graph showing mean Western blot 4-HNE/β-actin ratios ± SEM
in SN of 6 mice per group. (F) Double labeling of TH and 4-HNE in SN region of ventral midbrain. Images were captured at 60× magnification.
The SN zone is outlined in white dots. Inset pictures demonstrated colocalization of TH and 3-NT/4-HNE. ***P <0.001 vs the control group;
**P <0.01 vs the control group; *P <0.05 vs the MPTP group; #P <0.001 vs the MPTP group.
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Additionally, stereological counting of TH-positive neu-
rons in SN of MPTP-treated mice also showed > 60% re-
duction (Figure 6E).
Interestingly, diapocynin treatment improved MPTP-
induced damage of nigral TH-positive neurons and stri-
atal TH terminals (Figure 6A,E and Additional file 1:
Figure S1A). Consistent with these findings, Western
blot of TH in nigra and striatum also showed signifi-
cantly decreased TH protein levels in MPTP-treated
mice (Figure 6B,C,D). However, orally administered dia-
pocynin significantly prevented loss of nigral and striatal
TH in MPTP-treated mice (Figure 6B,C,D). Further as-
sessment of degenerating neurons in the nigral regions
by FJB staining revealed that diapocynin-treated MPTP
mice had fewer FJB-positive cells than untreated MPTP
mice (Additional file 1: Figure S1B). Collectively, these
results suggest that diapocynin is neuroprotective in the
MPTP mouse model of PD.
Diapocynin improves locomotor activities in
MPTP-injected mice
To assess the effectiveness of diapocynin against motor
deficits induced by MPTP, we measured various motor
performance parameters using VersaMax infrared com-
puterized activity monitoring system and a rotarod in-
strument (Accuscan). Behavioral function was assessed 4
days after the last dose of MPTP treatment. Representa-
tive motor activity maps of movement of saline-treated
control, MPTP and MPTP plus diapocynin-treated mice
are shown in Figure 7A. As expected, MPTP drastically
decreased movement in all directions. Diapocynin treat-
ment dramatically improved locomotion in the MPTP
plus diapocynin-treated group. Further analysis of loco-
motor activity data revealed that subacute MPTP treat-
ment markedly decreased horizontal activity (Figure 7B),
vertical activity (Figure 7C), total distance travelled
(Figure 7D), movement time (Figure 7E), observed
Figure 6 Diapocynin protects nigrostriatum in MPTP-treated mice. (A) Seven days after MPTP treatment mice were sacrificed, tyrosine
hydroxylase (TH)-3,3'-diaminobenzidine (DAB) immunostaining in the striatum and substantia nigra (SN) regions was performed
(2× magnifications). (B) Representative Western blots illustrating the expression of TH in SN and striatum. Bar graphs showing mean Western
blot TH/β-actin ratios ± SEM in (C) striatum and (D) SN of 6 mice per group. (E) Stereological counts of TH-positive dopaminergic neurons in the
SN of ventral midbrain. Data are means ± SEM of 8 to 10 mice per group. ***P <0.001 vs the control group; **P <0.01 vs the MPTP group;
#P <0.001 vs the MPTP group.
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stereotypies (Figure 7G), observed rearings (Figure 7H)
and rotarod performances at 20 rpm speed (Figure 7I),
consistent with our previous observations [16]. Add-
itionally, rest time was increased in the MPTP-treated
mice (Figure 7F). Notably, diapocynin treatment signifi-
cantly restored MPTP-induced locomotor and motor
co-ordination impairments for every endpoint measured
(Figure 7B,C,D,E,F,G,H,I).
Post-treatment with diapocynin rescues striatal
neurotransmitter depletion in MPTP-treated mice
Following characterization of the neuroprotective effect
of diapocynin in the typical subacute MPTP model, we
further examined whether diapocynin can intervene the
on-going degenerative processes in a post-treatment
paradigm. In order to test the efficacy of diapocynin
post-treatment, mice were treated with MPTP at a dose
of 25 mg/kg/day for 3 days followed by co-treatment
with MPTP and diapocynin (300 mg/kg/day) for 2 days.
Mice also received another 6 doses of diapocynin (300
mg/kg/day) and were sacrificed for neurotransmitter
analysis. As evident from Figure 8A,B,C, we observed
significantly reduced striatal dopamine (75%), DOPAC
(73%) and HVA (70%) in MPTP-treated mice. Im-
portantly, diapocynin post-treatment showed a reduction
of 52% of dopamine (Figure 8A), 50% of DOPAC
Figure 7 Diapocynin improves motor function in the MPTP-injected mice. (A) VersaPlot map showing moving track of mice. VersaMax data
showing (B) horizontal activity, (C) vertical activity, (D) distance travelled (cm); (E) movement time (sec); (F) rest time (sec), (G) number of
stereotypies, (H) number of rearings and (I) time spent on rotarod (sec) at rod speed 20 rpm. Data are means ± SEM of 8 to 10 mice per group.
***P <0.001 vs the control group; **P <0.01 vs the MPTP group; *P <0.05 vs the MPTP group; #P <0.01 vs the control group.
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(Figure 8B) and 40% of HVA (Figure 8C). Thus, these
results suggest that diapocynin slows the progression of
dopaminergic neurodegeneration in a post-treatment
MPTP mouse model of PD.
Diapocynin halts the disease progression in a chronic
MPTP mouse model
Although the subacute MPTP model is very efficient
for drug screening and elucidating molecular mechan-
isms, it does not recapitulate the chronic progression
of degenerative processes associated with PD. In our
experiment, we measured whether diapocynin effi-
ciently protected nigrostriatum in a chronic MPTP
model (Figure 8D,E,F). As expected, chronic MPTP ad-
ministration led to approximately 80% loss of dopa-
mine (Figure 8D), 60% loss of DOPAC (Figure 8E) and
70% loss of HVA (Figure 8F). Consistent with observa-
tions in the subacute MPTP model, diapocynin
significantly restored dopamine (P <0.01; Figure 8D),
DOPAC (P <0.05; Figure 8E) and HVA (P <0.05;
Figure 8F) in striatum, demonstrating that oral diapo-
cynin treatment can slow the progressive neurodegen-
erative process in the nigrostriatal dopaminergic
system.
Discussion
Neuroinflammation and oxidative stress are now well
recognized as key pathophysiological events contributing
to the progressive loss of nigral dopaminergic neurons
in PD [2-4]. However, an effective neuroprotective ther-
apy to halt the progression of the disease is not available.
Here, we report the anti-inflammatory and antioxidative
properties of a synthetic analog of apocynin in the
MPTP mouse model of PD. Recent studies have shown
conversion of apocynin to diapocynin (apocynin dimer)
in vivo, which prevents the assembly and activation of
the NADPH oxidase complex [13]. Additionally, diapo-
cynin is 13-fold more lipophilic than apocynin [22].
Figure 8 Diapocynin suppresses disease progression in the subacute MPTP mouse model of Parkinson’s disease (PD) and protects
striatal neurotransmitter depletion in the chronic MPTP mouse model of PD. For disease progression study, mice were treated with MPTP
(25 mg/kg/day) for 5 days. Diapocynin (300 mg/kg/day) treatment started on the 4th day of MPTP injection and continued for another 8 days.
Mice were sacrificed 1 day after the last dose of diapocynin and striatal (A) dopamine, (B) 3,4-dihydroxyphenyl-acetic acid (DOPAC) and (C)
homovanillic acid (HVA) were measured by high-performance liquid chromatography (HPLC). For chronic treatment, mice were treated with 2
doses of MPTP (25 mg/kg/day, s.c.) and 2 doses of probenecid (250 mg/kg/day, i.p.) per week for 5 weeks. Control mice received only saline. One
week prior to MPTP/probenecid treatment, one group of mice received 3 doses of diapocynin (100 mg/kg/day, gavage) and this treatment
continued for 12 consecutive weeks. Another batch of mice received 3 doses of diapocynin (100 mg/kg/day, gavage) in a week for consecutive
12 weeks. Immediately after treatment, mice were sacrificed and striatal (D) dopamine, (E) DOPAC and (F) HVA were measured by HPLC. Data are
means ± SEM of 8 to 10 mice per group. ***P <0.001 vs the control group; **P <0.01 vs the MPTP group; *P <0.05 vs the MPTP group.
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Here, we show that diapocynin inhibits MPTP-induced
activation and expression of both iNOS and gp91phox
in activated glial cells, suggesting that diapocynin has
anti-inflammatory properties against neurotoxic stress.
Diapocynin also attenuates the formation of ONOO-
and 4-HNE in dopaminergic neurons in response to
various stimuli, further confirming the antioxidant prop-
erties of this compound.
Importantly, diapocynin also protects against MPTP-
induced motor deficits, striatal neurotransmitter
depletion and nigrostriatal degeneration. Furthermore,
diapocynin is effective in post-treatment paradigms as
well as in chronic neurodegenerative models of PD.
Derivatives of natural compounds, such as diapocynin,
are a key translational approach for the development of
therapies for PD. To our knowledge, this is the first re-
port showing anti-inflammatory, antioxidative and neu-
roprotective properties of a novel apocynin derivative in
animal models of PD.
NADPH oxidase has emerged as a major source of
oxidative stress in the brain, particularly in neurodegen-
erative disorders, such as PD, Alzheimer's disease, ALS
and multiple sclerosis [23]. Apocynin has been shown to
inhibit NADPH oxidase, which generates ROS during in-
flammatory processes [10]. Although the mechanism of
inhibition of apocynin is not clear, it is thought to pre-
vent the recruitment of cytosolic NADPH oxidase sub-
unit p47phox to the membrane, thereby inhibiting
NADPH oxidase activity. Apocynin has been shown to
attenuate superoxide formation and oxidative stress
in vivo as well as reduce acute inflammation in lung and
spinal cord [24-26]. Furthermore, apocynin administered
at a dose of 300 mg/kg/day protects against oxidative
damage induced by cerebral ischemia [27] and ALS [14].
In contrast, recent studies have shown that apocynin
failed to show any improvement in transgenic animal
models of Alzheimer's disease [28] or ALS [29]. In vitro
studies in dopaminergic neuronal cell lines and primary
cultures also demonstrated a protective role of apocynin
in 1-methyl-4-phenyl-pyridinium ion (MPP+) or MPTP-
induced NADPH oxidase mediated apoptotic cell death
[10,30]. Also, a pro-oxidative nature of apocynin has
been shown in non-phagocytic cells, where it increases
ROS production significantly [31]. Thus, these studies
suggest that the development of an improved apocynin
related compound may yield a better neuroprotective
agent for treatment of PD.
In the central nervous system, glial activation involving
astrocytes, microglial cells, lymphocyte infiltration, and
production of proinflammatory mediators including
cytokines, chemokines, prostaglandins, and reactive
mediators, such as reactive nitrogen species (RNS) and
ROS, are all hallmarks of inflammatory reactions. MPP+,
the active metabolite of MPTP, is believed to be
responsible for glial activation mediated inflammation
and neurodegeneration [2]. In our study, we also
observed marked activation of microglia and astrocytes,
measured by Western blotting and immunohistochemis-
try after MPTP treatment in SN, and diapocynin signifi-
cantly attenuated MPTP-induced microgliosis and
astrogliosis (Figure 2).
Nuclear factor kappa B (NF-κB), a transcription factor,
has been shown to be an important regulator of the
microglial and astroglial proinflammatory reactions in
the SN. The promoter regions of proinflammatory mole-
cules, including iNOS, contain the binding sites for NF-
ĸB [19]. Astroglia and microglia in the healthy brain do
not express iNOS, but following toxic or inflammatory
damage, reactive astroglia and microglia express iNOS
in the brain [32]. Studies have shown that MPTP treat-
ment produces significantly reduced neuronal loss in
mice deficient in iNOS compared to their wild-type
counterparts [33].
In this study, we demonstrate that diapocynin, a
pharmacological inhibitor of microglial NADPH oxi-
dase, effectively attenuates MPTP-induced increases in
iNOS expression (Figure 3), suggesting the potential
use of diapocynin as an anti-inflammatory agent. RNS
as well as ROS play a pivotal role in oxidative stress
and inflammation in PD. NADPH oxidase, which is a
major ROS-producing enzyme of microglial cells, med-
iates superoxide production and controls the levels of
pro-inflammatory neurotoxic factors, such as TNFα
and IL-1β [34]. In our study, we demonstrate that dia-
pocynin attenuates MPTP-induced expression of
microglial gp91phox in SN and thereby reduces the
production of ROS (Figure 4).
Besides having direct toxic effects on nigral dopamin-
ergic neurons, nitric oxide (•NO) and superoxide O2
−
derived from astrocytes and microglia can react to form
the highly reactive nitrogen species peroxynitrite
(ONOO-). Peroxynitrite causes nitration of tyrosine resi-
dues in various proteins including TH and α-synuclein
[21,35]. Peroxinitrite mediated nitration of TH is asso-
ciated with reduced enzymatic activity.
3-NT is widely used as a marker of nitrative damage.
Here, we found increased expression of 3-NT in dopa-
minergic neurons in SN of MPTP-treated mice, predom-
inantly co-localized with TH-positive dopaminergic
neurons (Figure 5A,B,C). However, diapocynin signifi-
cantly decreased the MPTP-induced increase in 3-NT in
dopaminergic neurons in the SN.
Along with peroxynitrite, levels of 4-HNE, an unsat-
urated aldehyde generated during lipid peroxidation,
were also significantly increased in the SN of PD
brains compared to controls [36]. 4-HNE has been
demonstrated to block mitochondrial respiration and
induce caspase-dependent apoptosis [37,38]. In our
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study, we showed increased expression of 4-HNE, a
marker of oxidative damage in the SN of MPTP-
treated mice, which was colocalized in the cytosol of
TH-positive dopaminergic neurons (Figure 5D,E,F).
However, diapocynin significantly decreased the amount
of 4-HNE in the MPTP-treated SN, indicating that dia-
pocynin acted by attenuating ROS generation.
The lack of an effective therapy to halt the progression
of PD has been a longstanding challenge in the field. Ad-
ministration of a dopamine agonist or levodopa has been
the leading treatment for PD symptoms, but these treat-
ments do not affect disease progression. Various putative
neuroprotective agents, including glial cell line-derived
neurotrophic factor (GDNF), brain-derived neurotrophic
factor (BDNF), TGF-β and other small molecule com-
pounds, have been tested in animal models of PD
[39,40]. However, most of these compounds failed in ei-
ther pre-clinical trials or human trials due to their in-
ability to cross the blood-brain barrier or due to limited
bioavailability. Moreover, they also caused adverse side
effects. Hence, understanding the mechanism of the dis-
ease process and development of a successful neuropro-
tective therapeutic approach to halt the disease
progression are of principal importance in PD research.
Diapocynin has several advantages compared to other
experimental drugs, including its parent compound
apocynin. These include: (1) co-treatment of diapocynin
and MPTP profoundly attenuated MPTP-induced glial
activation and proinflammatory events, (2) diapocynin
suppressed oxidative stress in vivo in the SN of MPTP-
treated mice, (3) diapocynin treatment improved MPTP-
induced behavioral deficits, (4) diapocynin protected
TH-positive dopaminergic neurons from MPTP toxicity
and restored the level of dopamine and its metabolites,
and (5) oral administration of diapocynin on day 4, after
the disease has been initiated by MPTP, also restored the
levels of striatal dopamine neurotransmitters in MPTP-
treated mice, suggesting that diapocynin could attenuate
disease progression.
It is noteworthy that diapocynin does not interfere
with MPTP metabolism, demonstrating the true neuro-
protective effect in the MPTP model. Also, diapocynin is
fairly nontoxic, as the mice treated with diapocynin
alone (300 mg/kg/day) for 12 days did not show any sign
of behavioral imparities and their neurotransmitter levels
were not different from the saline-treated control mice
(Figures 1E,F,G,H and 8D,E,F). Another advantage is that
diapocynin can be administered orally by gavage. Being a
lipophilic molecule, diapocynin easily crosses the blood-
brain barrier and enters the SN (>1.5 μg/mg tissue) and
striatum (>0.9 μg/mg tissue) regions of brain, as
detected by LC/MS/MS (Figure 1C and D). We had to
use 300 mg/kg oral dose in order to achieve a desired
neuroprotective effect. Although the exact reason for the
requirement of a high dose of diapocynin is not clear, it
is possible that diapocynin rapidly undergoes metabolic
degradation similar to apocynin [41]. Nevertheless, fu-
ture studies are needed to clarify the metabolic fate of
diapocynin in vivo. Taken together, our results demon-
strate that diapocynin is a promising neuroprotective
agent that deserves further exploration for its use in
clinical settings.
Conclusions
In summary, our results demonstrate that oral adminis-
tration of diapocynin, a metabolite of apocynin, attenu-
ates key neuroinflammatory events, including microglial
and astroglial activation, iNOS upregulation, and oxida-
tive and nitrative damage, in a MPTP mouse model of
PD. Importantly, diapocynin treatment protects against
nigral dopaminergic neuronal damage and behavioral
deficits in the animal model of PD. This systematic
characterization of the anti-inflammatory and neuropro-
tective efficacy of diapocynin in pre-clinical models of
PD will facilitate further exploration of the compound
for clinical application in the future.
Additional file
Additional file 1: Figure S1. Diapocynin protects dopaminergic
neurons in the MPTP model of PD. Mice were administered diapocynin
(300 mg/kg/day) by oral gavage 24 h before MPTP treatment, and co-
treatment with MPTP (25 mg/kg/day) continued for 5 days, and post-
treatment with MPTP (25 mg/kg/day) continued for 6 days. Control mice
received 10% ethanol in saline. Seven days after the last MPTP injection,
mice were sacrificed and substantia nigra (SN) sections were processed
for TH. (A) Double labeling of tyrosine hydroxylase (TH) and Fluoro-Jade
B (FJB) in SN sections. (B) TH-DAB pictures were captured at 10×
magnification and TH and FJB double labeled pictures were captured at
20× magnification.
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